Category Archives: X-396 – ensartinib from Xcovrery

X-396 update and info on liquid biopsy

Abstract 9056 is an update of info previously published on this site. The study involved 60 patients of whom 30 were ALK+ NSCLC. Of that 30, 19 (60%) had partial responses (PR). 8 patients were Crizotinib naive and of them … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects, X-396 - ensartinib from Xcovrery | Leave a comment

Ensartinib (X396) trial update

63 patients in trial but only 35 are ALK+, NSCLC, and treated at 200 to 250 mg daily. Of those, 8 were ALK inhibitor naive, 7 (88%) had an objective response. 19 patients had received Crizotinib but not another ALK … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects, X-396 - ensartinib from Xcovrery | Leave a comment

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Updated Clinical Data on X-396

The reported research found that the objective response rate was 88% (7/8) in ALK-TKI treatment-naïve patients, and 84% (10/12) in crizotinib-resistant patients. http://www.cbs19.tv/story/30920448/xcovery-announces-updated-clinical-data-on-x-396-in-patients-with-alk-non-small-cell-lung-cancer-at-the-4th-aacr-iaslc-international-joint-conference

Posted in Lung cancer, Potential Treatments, Research, Resistance to treatment, X-396 - ensartinib from Xcovrery | Leave a comment

Xcovery updates results on x-396

At the time of data cutoff, 41 patients were enrolled with tumor types including NSCLC, head and neck, small cell lung, colorectal and breast cancers. The NSCLC (n=33) patient group included ALK-positive patients (n=23) who were either crizotinib-naïve (n=5) or … Continue reading

Posted in Brain metastases, Lung cancer, Regulatory applications & approvals, Research, X-396 - ensartinib from Xcovrery | Leave a comment

Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014. It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

List of 8 ALK Inhibitors in trials

List of 8 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Pfizer – Crizotinib (2011 initial, 2013 final) Novartis – Ceritinib (2014 initial) FDA Breakthrough Status Chugai – Alectinib (approved in Japan in 2014) Ariad … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Regulatory applications & approvals, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

GRACE conference in Boston

There were several presentations as part of the Grace conference in Boston on Saturday, September 6. So far this is the only one I have found online. PowerPoint presentation by Dr. Alice Shaw on 8 or 9 new ALK inhibitors … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | 1 Comment

Xcovery poster update on X396

Not much new compared to press release Responses were observed in 2 patients with centralized nervous system mets. That is out of 11 ALK+ patients (no idea how many had brain mets). 3 patients on treatment over 40 weeks. No … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects, X-396 - ensartinib from Xcovrery | 1 Comment

Abstracts from upcoming ASCO conference

Overall, I would say the results were disappointing, fewer patients had progressed far enough for meaningful results than I had hoped for. However, given that the data cut offs were usually around December and most of the trials were near … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment